Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus

被引：196

作者：

Chen, W. -W. ^{[1
]}

Li, L. ^{[2
,3
]}

Yang, G. -Y. ^{[1
]}

Li, K. ^{[1
]}

Qi, X. -Y. ^{[1
]}

Zhu, W. ^{[1
]}

Tang, Y. ^{[4
]}

Liu, H. ^{[5
]}

Boden, G. ^{[6
,7
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 2, Dept Endocrinol, Chongqing 400010, Peoples R China

[2] Chongqing Med Univ, Minist Educ, Dept Clin Biochem, Chongqing, Peoples R China

[3] Chongqing Med Univ, Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China

[4] Centocor Inc, Oncol Res, Malvern, PA 19355 USA

[5] Univ Mississippi, Med Ctr, Dept Pediat, Jackson, MS 39216 USA

[6] Temple Univ, Sch Med, Div Endocrinol Diabet Metab, Philadelphia, PA 19122 USA

[7] Temple Univ, Sch Med, Clin Res Ctr, Philadelphia, PA 19122 USA

来源：

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2008年 / 116卷 / 01期

关键词：

FGF-21; insulin resistance; T2DM;

D O I：

10.1055/s-2007-985148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and nondiabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82 +/- 0.65 vs. 1.53 +/- 0.60 mu g/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose (r = -0.31, P< 0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA(IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.

引用

页码：65 / 68

页数：4

共 15 条

[1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2] 2-S
[3] Bhushan A, 2001, DEVELOPMENT, V128, P5109
[4] Fibroblast growth factor 19 increases metabolic rate I and reverses dietary and leptlin-deficient diabetes
Fu, L
John, LM
Adams, SH
Yu, XX
Tomlinson, E
Renz, M
Williams, PM
Soriano, R
Corpuz, R
Moffat, B
Vandlen, R
Simmons, L
Foster, J
Stephan, JP
Tsai, SP
Stewart, TA
[J]. ENDOCRINOLOGY, 2004, 145 (06) : 2594 - 2603
[5] FGF-21 as a novel metabolic regulator
Kharitonenkov, A
Shiyanova, TL
Koester, A
Ford, AM
Micanovic, R
Galbreath, EJ
Sandusky, GE
Hammond, LJ
Moyers, JS
Owens, RA
Gromada, J
Brozinick, JT
Hawkins, ED
Wroblewski, VJ
Li, DS
Mehrbod, F
Jaskunas, SR
Shanafelt, AB
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) : 1627 - 1635
[6] Reduced phosphorylation of transcription factor Elk-1 in cultured fibroblasts of a patient with premature aging syndrome and insulin resistance
Knebel, B
Avci, H
Bullmann, C
Kotzka, J
Müller-Wieland, D
[J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (02) : 94 - 101
[7] Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes
Konishi, M
Mikami, T
Yamasaki, M
Miyake, A
Itoh, N
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) : 12119 - 12122
[8] HOMEOSTASIS MODEL ASSESSMENT - INSULIN RESISTANCE AND BETA-CELL FUNCTION FROM FASTING PLASMA-GLUCOSE AND INSULIN CONCENTRATIONS IN MAN
MATTHEWS, DR
HOSKER, JP
RUDENSKI, AS
NAYLOR, BA
TREACHER, DF
TURNER, RC
[J]. DIABETOLOGIA, 1985, 28 (07) : 412 - 419
[9] Identification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T
Nakatake, Y
Konishi, M
Itoh, N
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2000, 1492 (01): : 203 - 206
[10] Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain
Nishimura, T
Utsunomiya, Y
Hoshikawa, M
Ohuchi, H
Itoh, N
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1444 (01): : 148 - 151

← 1 2 →